Literature DB >> 26980016

MAGI-2 in prostate cancer: an immunohistochemical study.

Jeffery Goldstein1, Alexander D Borowsky2, Rajen Goyal3, Joseph T Roland4, Shanna A Arnold5, Lan L Gellert6, Peter E Clark7, Omar Hameed8, Giovanna A Giannico9.   

Abstract

Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2) is a scaffolding protein that links cell adhesion molecules, receptors, and signaling molecules to the cytoskeleton and maintains the architecture of cell junctions. MAGI-2 gene rearrangements have recently been described in prostate cancer. We studied the immunohistochemical expression of MAGI-2 protein in prostate tissue. Seventy-eight radical prostatectomies were used to construct 3 tissue microarrays consisting of 512 cores, including benign tissue, benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia (HGPIN), and adenocarcinoma, Gleason patterns 3 to 5. Immunohistochemistry for phosphatase and tensin homologue (PTEN) and double-stain MAGI-2/p63 was performed and analyzed by visual and image analysis, the latter as percent of analyzed area (%AREA), and mean optical density multiplied by %AREA (STAIN). By visual and image analysis, MAGI-2 was significantly higher in adenocarcinoma and HGPIN compared with benign (benign versus HGPIN P < .001; benign versus adenocarcinoma, P < .001). HGPIN and adenocarcinoma did not significantly differ by either modality. Using visual intensity to distinguish benign tissue and adenocarcinoma, a receiver operating curve yielded an area under the curve of 0.902. A STAIN threshold of 1470 yielded a sensitivity of 0.66 and specificity of 0.96. There was a significant correlation between PTEN and MAGI-2 staining for normal and benign prostatic hyperplasia, but this was lost in HGPIN and cancer. We conclude that MAGI-2 immunoreactivity is elevated in prostate cancer and HGPIN compared with normal tissue, and suggest that MAGI-2 may contribute to prostate carcinogenesis. This is the first report of MAGI-2 staining by immunohistochemistry in prostate cancer.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Image analysis; Immunohistochemistry; MAGI-2; PTEN; Prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 26980016     DOI: 10.1016/j.humpath.2016.01.003

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  3 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

2.  Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.

Authors:  Jagpreet S Nanda; Wisam N Awadallah; Sarah E Kohrt; Petra Popovics; Justin M M Cates; Janni Mirosevich; Peter E Clark; Giovanna A Giannico; Magdalena M Grabowska
Journal:  Prostate       Date:  2020-07-21       Impact factor: 4.104

3.  High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas.

Authors:  Ping Mei; C Eric Freitag; Lai Wei; Yunxiang Zhang; Anil V Parwani; Zaibo Li
Journal:  Diagn Pathol       Date:  2020-05-11       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.